OncoMatch/Clinical Trials/NCT06776770
A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer
Is NCT06776770 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Adebrelimab for gastric cancer.
Treatment: Adebrelimab — In this study, the combination of Adebrelimab (PD-L1 monoclonal antibody) on the basis of standard treatment (two-drug chemotherapy regimen of fluorouracil and platinum drugs) may enhance the immune response in order to enhance the killing effect on tumor cells and bring survival benefits to patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Biomarker criteria
Required: HER2 (ERBB2) negative or unknown
Human epidermal growth factor receptor 2 negative or unknown
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: PD-1/PD-L1 inhibitor
Previous treatment with PD-1/PD-L1 antibodies, cytotoxic T lymphocyte-associated antigen-4 antibodies, or other PD-1/PD-L1 inhibitors
Cannot have received: immunosuppressive drug
Exception: nasal and inhaled corticosteroids or physiologic doses of systemic steroid hormones (i.e., up to 10 mg/day of prednisolone or pharmacophysiologically equivalent doses of other corticosteroids)
Previous use of immunosuppressive drugs within 14 days prior to the first dose of study drug
Lab requirements
Blood counts
Neutrophil count ≥ 1,500/mm3; Platelet count ≥ 75,000/mm3; Hemoglobin ≥ 8 G/dL
Kidney function
Serum creatinine ≤ 1.5x ULN or creatinine clearance ≥ 40 ml/min; Urine protein < 2+; if urine protein ≥ 2+, 24-hour urine protein quantification ≤ 1 G
Liver function
Total bilirubin ≤ 1.5x ULN; AST/ALT ≤ 2.5x ULN, and ≤ 5x ULN for patients with liver metastasis
Cardiac function
International normalized ratio (INR) ≤ 1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5x ULN; Thyroid-stimulating hormone (TSH) ≤ ULN; if abnormal, T3 and T4 levels should be investigated, and normal T3 and T4 levels can be included
Adequate organ and bone marrow function, as defined below: A) Neutrophil count (ANC) ≥ 1,500/mm3 (1.5 × 10 ^ 9/L); B) Platelet count (PLT) ≥ 75,000/mm3 (75 × 10 ^ 9/L); C) hemoglobin (Hb) ≥ 8 G/dL (80 G/L); D) Serum creatinine ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance ≥ 40 ml/min; E) Total bilirubin (BIL) ≤ 1.5 times the upper limit of normal (ULN); F) Aspartate transaminase or Alanine transaminase ≤ 2.5 times the upper limit of normal (ULN), and ≤ 5 × ULN for patients with liver metastasis; G) International normalized ratio (INR) ≤ 1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 times ULN; H) Urine protein < 2 +; if urine protein ≥ 2 +, 24-hour urine protein quantification shows that protein must be ≤ 1 G; I) Thyroid-stimulating hormone (TSH) ≤ upper limit of normal (ULN); if abnormal, T3 and T4 levels should be investigated, and normal T3 and T4 levels can be included
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify